AVNS - Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading

2024-03-24 08:34:00 ET

Summary

• Atrion Corporation, a healthcare company focused on fluid delivery products, has experienced a decline in revenue, profits, and cash flows.
• The drop in sales of fluid delivery products, which account for 42% of overall revenue, has severely impacted the company's top line.
• Despite the potential for improvement in the future, the stock is currently expensive compared to similar companies, warranting a cautious outlook and a downgrade to a 'sell' rating.

Sometimes, when you have a company that is doing well from a growth perspective, you can give a little too much leeway in concluding how attractive the company is from an investment perspective. This could be rather painful. An example of this happening with a firm I looked into involves Atrion Corporation ( ATRI ), a firm that is focused on producing and selling products associated with fluid delivery. For the most part, its emphasis is on cardiovascular and ophthalmic offerings. Examples include, but are not limited to, cardiac surgery vacuum relief valves, inflation devices for balloon catheter dilation, and more. It even sells medical devices which disinfect contact lenses and balloon catheters for children and adults alike....

For further details see: